Chambers Laura M, Yao Meng, Morton Molly, Gruner Morgan, Chichura Anna, Costales Anthony B, Horowitz Max, Rose Peter G, Michener Chad M, Debernardo Robert
Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH, United States.
Division of Gynecologic Oncology, Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
Gynecol Oncol Rep. 2022 Feb 28;40:100951. doi: 10.1016/j.gore.2022.100951. eCollection 2022 Apr.
To evaluate travel distance in women with advanced or recurrent epithelial ovarian cancer (OC) undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) and the subsequent impact upon outcomes.
An IRB-approved single-institution prospective registry was queried for women with OC who underwent HIPEC from 1/1/2009-12/1/2020. Demographic, oncologic, and surgical data were recorded. The patient's home zip code was compared to the institutional zip code to determine travel distance using Google Maps. Patients were divided into three strata for analysis: 1) local: ≤50 miles, 2) regional: 51-99 miles, and 3) distant: ≥100 miles and univariate analysis was performed.
Of 127 women, the median distance travelled was 57.0 miles (IQR: 20.6, 84.6). There were no significant differences in mild (28.3% vs. 26.3 vs. 24.1%), moderate (21.7% vs. 15.8% vs. 17.2%) or severe postoperative complications (11.7% vs. 5.3% vs. 17.2%) (p = 0.75) for local, regional and distant patients, respectively. There was no difference in progression-free survival (17.4 vs. 22.2 vs. 12.8 months, p > 0.05) or overall survival (57.3 vs. 61.6 vs. 29.2 months, p > 0.05) for local, regional or distant patients, respectively.
This study demonstrates that women with OC are willing to travel for HIPEC, with over 50% traveling > 50 miles. Our results suggest that women who travel for HIPEC procedures are not at increased risk for perioperative complications or worse oncologic outcomes than those local to HIPEC centers.
评估接受细胞减灭术联合热灌注化疗（HIPEC）的晚期或复发性上皮性卵巢癌（OC）女性患者的就诊距离，以及该距离对治疗结果的后续影响。
查询了一家机构审查委员会（IRB）批准的单机构前瞻性登记数据库，纳入2009年1月1日至2020年12月1日期间接受HIPEC治疗的OC女性患者。记录人口统计学、肿瘤学和手术数据。使用谷歌地图将患者的家庭邮政编码与机构邮政编码进行比较，以确定就诊距离。患者分为三个层次进行分析：1）本地：≤50英里；2）区域：51 - 99英里；3）远处：≥100英里，并进行单因素分析。
127名女性患者的中位就诊距离为57.0英里（四分位间距：20.6，84.6）。本地、区域和远处患者的轻度（分别为28.3%对26.
